Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

PRICE TALK: Cheplapharm E750m 6NC2 sr sec notes 6.75%-7.00%, pxg today

HYC European Market: Commentary - General

+++Updates with timing+++

Cheplapharm Arzneimittel GmBH EUR750m 144A/Reg S sr sec notes due 2032 (6y). NC2 (MWC B+50bp) (50%,25%,par). Equity claw: 2y 40%. Special call: 10% per year the 1st 3 years at 103. B3/B/B+ (stable/stable/stable). Via Citi/DB (D&B) jt glocos and physical books/Barc/BofA/Commerz/GS/JPM/ING/UBS/UniCredit jt books. No reg rights. List ISE. NY law. CoC at 101. Denoms: 100kx1k. IPT: 7.00%-7.25%.

Price talk: 6.75%-7.00%

Roadshow (small in person group meetings) 01/26-27 (investor call 11am UKT 01/26). Books close at 1:30pm UKT 01/27. Pricing 01/27 UK afternoon. UOP: along with EUR14m cash on hand, to refinance the existing EUR575m 4.375% sr sec notes due 01/15/28 (callable at 100) and US$215m 5.50% sr sec notes due 01/15/28 (callable at 100). Privately owned by Sebastian Braun, Co-CEO (50%), and Dr Bianca Juha, Chief Scientific Officer (50%). Biz: specialty pharmaceuticals. HQ: Greifswald, Germany.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.